Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

(European Society for Medical Oncology) The first phase III study of PD-L1 inhibitor atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, researchers reported today at the ESMO 2016 Congress in Copenhagen.